May 7 /PRNewswire/ -- BioVisioN GmbH & Co. KG, the German biotechnology company, announced that it has formed a long-term, strategic collaboration with the Applied Biosystems Group (NYSE: ABI - news), an Applera Corporation business. The two companies will collaborate on the joint development of tools, techniques, and applications for the growing proteomics market. They will also establish a European reference laboratory for Proteomics and Peptidomics technologies at BioVisioN headquarters in Hannover, Germany. Peptidomics, pioneered at BioVisioN, is the application of human peptide research for diagnosis and treatment of human disease.
The partnership will combine BioVisioN's cutting-edge technology in protein and peptide analysis with Applied Biosystems market-leading life science research tools in biochromatography, MALDI-TOF mass spectrometry, and informatics to create integrated solutions for protein research. These systems are expected to improve precision and throughput for discovering clinically relevant proteins and peptides for the development of drugs and diagnostic tests in the pharmaceutical industry.
``Our collaboration with Applied Biosystems can lead to the next great step in the post-genome era,'' said BioVisioN CEO Peter Schulz-Knappe. ``The integrated technologies of BioVisioN and Applied Biosystems are expected to accelerate the discovery of disease-related gene products, and the future development of new drugs and diagnostics for a broad variety of diseases.''
``BioVisioN has developed some very creative approaches to protein and peptide purification and analysis,'' said Jay Smith, director and product line manager for MALDI-TOF MS and biochromatography at Applied Biosystems. ``We see them as a key partner in shaping and developing our next generation of high-throughput tools.''
The collaboration builds on the successful relationship between BioVisioN and Applied Biosystems German subsidiary that began in 1999.
BioVisioN GmbH & Co. KG, based in Hannover, Germany, is dedicated to the discovery of human gene products such as proteins and peptides relevant to the diagnosis and treatment of disease. Using its proprietary technology, BioVisioN analyses human body fluids and tissues for potential candidates. Customers in the pharmaceuticals industry license the results for the development of drugs and diagnostics. BioVisioN is an independent biotechnology company, founded in 1997 and financed by venture capital. For further information about BioVisioN, please visit the company website at www.biovision.de or phone to: +49(0)511-538896-80. |
